Table 2

Immunohistochemical analysis of human prostate carcinoma in the bone of control and treated nude mice

Treatment groupaBoneMuscle
Tumor cellsEndothelial cellsTumor cellsEndothelial cells
PCNA+bTUNEL+bCD31+b% TUNEL (range)cPCNA+bTUNEL+bCD31+b% TUNEL (range)c
Control136 ± 298 ± 254 ± 162 (0–7)130 ± 227 ± 252 ± 213 (0–6)
Taxol78 ± 33d32 ± 15d38 ± 165 (0–16)75 ± 29d19 ± 14d36 ± 166 (0–15)
PKI 16688 ± 20d29 ± 14d35 ± 149 (0–15)d122 ± 207 ± 350 ± 184 (0–8)
PKI 166+ Taxol39 ± 16d,e71 ± 20d,e20 ± 14d,e16 (0–23)d,e72 ± 25d34 ± 17d34 ± 196 (0–17)
  • a Human prostate cancer cells were injected into the tibia of nude mice. Three days later, groups of mice were treated with oral feedings of PKI 166 (100 mg/kg, thrice weekly) alone, weekly i.p. injection of Taxol (200 μg) alone, PKI 166 and Taxol, or water (control).

  • b Mean ± SD.

  • c Median of the ratio of apoptotic endothelial cells to total number of endothelial cells in 5–10 random 0.011-mm2 fields at ×400.

  • d P < 0.001 as compared with controls.

  • e P < 0.05 as compared with the group treated with Taxol alone.